These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 22337204

  • 1. Factors that restrict the cell permeation of cyclic prodrugs of an opioid peptide, part 4: Characterization of the biopharmaceutical and physicochemical properties of two new cyclic prodrugs designed to be stable to oxidative metabolism by cytochrome P-450 enzymes in the intestinal mucosa.
    Nofsinger R, Borchardt RT.
    J Pharm Sci; 2012 Sep; 101(9):3500-10. PubMed ID: 22337204
    [Abstract] [Full Text] [Related]

  • 2. Factors that restrict the cell permeation of cyclic prodrugs of an opioid peptide, part 3: Synthesis of analogs designed to have improved stability to oxidative metabolism.
    Nofsinger R, Fuchs-Knotts T, Borchardt RT.
    J Pharm Sci; 2012 Sep; 101(9):3486-99. PubMed ID: 22411763
    [Abstract] [Full Text] [Related]

  • 3. Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides.
    Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.
    J Med Chem; 2006 Feb 23; 49(4):1261-70. PubMed ID: 16480263
    [Abstract] [Full Text] [Related]

  • 4. Factors that restrict intestinal cell permeation of cyclic prodrugs of an opioid peptide (DADLE): Part II. Role of metabolic enzymes in the intestinal mucosa.
    Ouyang H, Chen W, Andersen TE, Steffansen B, Borchardt RT.
    J Pharm Sci; 2009 Jan 23; 98(1):349-61. PubMed ID: 18537150
    [Abstract] [Full Text] [Related]

  • 5. Optimizing oral absorption of peptides using prodrug strategies.
    Borchardt RT.
    J Control Release; 1999 Nov 01; 62(1-2):231-8. PubMed ID: 10518655
    [Abstract] [Full Text] [Related]

  • 6. Factors that restrict the intestinal cell permeation of cyclic prodrugs of an opioid peptide (DADLE): Part I. Role of efflux transporters in the intestinal mucosa.
    Ouyang H, Chen W, Andersen TE, Steffansen B, Borchardt RT.
    J Pharm Sci; 2009 Jan 01; 98(1):337-48. PubMed ID: 18537149
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of the permeation characteristics of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs across the blood-brain barrier using an in situ perfused rat brain model.
    Chen W, Yang JZ, Andersen R, Nielsen LH, Borchardt RT.
    J Pharmacol Exp Ther; 2002 Nov 01; 303(2):849-57. PubMed ID: 12388672
    [Abstract] [Full Text] [Related]

  • 8. Synthesis and conformational analysis of a coumarinic acid-based cyclic prodrug of an opioid peptide with modified sensitivity to esterase-catalyzed bioconversion.
    Ouyang H, Vander Velde DG, Borchardt RT, Siahaan TJ.
    J Pept Res; 2002 Apr 01; 59(4):183-95. PubMed ID: 11972752
    [Abstract] [Full Text] [Related]

  • 9. The effect of conformation of the acyloxyalkoxy-based cyclic prodrugs of opioid peptides on their membrane permeability.
    Gudmundsson OS, Vander Velde DG, Jois SD, Bak A, Siahaan TJ, Borchardt RT.
    J Pept Res; 1999 Apr 01; 53(4):403-13. PubMed ID: 10406218
    [Abstract] [Full Text] [Related]

  • 10. Synthesis and evaluation of the physicochemical properties of esterase-sensitive cyclic prodrugs of opioid peptides using coumarinic acid and phenylpropionic acid linkers.
    Wang B, Nimkar K, Wang W, Zhang H, Shan D, Gudmundsson O, Gangwar S, Siahaan T, Borchardt RT.
    J Pept Res; 1999 Apr 01; 53(4):370-82. PubMed ID: 10406215
    [Abstract] [Full Text] [Related]

  • 11. Stability of oxymethyl-modified coumarinic acid cyclic prodrugs of diastereomeric opioid peptides in biological media from various animal species including human.
    Liederer BM, Borchardt RT.
    J Pharm Sci; 2005 Oct 01; 94(10):2198-206. PubMed ID: 16136552
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Significant differences in the disposition of cyclic prodrugs of opioid peptides in rats and guinea pigs following IV administration.
    Liederer BM, Phan KT, Ouyang H, Borchardt RT.
    J Pharm Sci; 2005 Dec 01; 94(12):2676-87. PubMed ID: 16258984
    [Abstract] [Full Text] [Related]

  • 14. Acyloxyalkoxy-based cyclic prodrugs of opioid peptides: evaluation of the chemical and enzymatic stability as well as their transport properties across Caco-2 cell monolayers.
    Bak A, Gudmundsson OS, Friis GJ, Siahaan TJ, Borchardt RT.
    Pharm Res; 1999 Jan 01; 16(1):24-9. PubMed ID: 9950274
    [Abstract] [Full Text] [Related]

  • 15. Synthesis and evaluation of the physicochemical properties of esterase-sensitive cyclic prodrugs of opioid peptides using an (acyloxy)alkoxy linker.
    Bak A, Siahaan TJ, Gudmundsson OS, Gangwar S, Friis GJ, Borchardt RT.
    J Pept Res; 1999 Apr 01; 53(4):393-402. PubMed ID: 10406217
    [Abstract] [Full Text] [Related]

  • 16. Coumarinic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeability.
    Gudmundsson OS, Pauletti GM, Wang W, Shan D, Zhang H, Wang B, Borchardt RT.
    Pharm Res; 1999 Jan 01; 16(1):7-15. PubMed ID: 9950272
    [Abstract] [Full Text] [Related]

  • 17. The effect of conformation on the membrane permeation of coumarinic acid- and phenylpropionic acid-based cyclic prodrugs of opioid peptides.
    Gudmundsson OS, Jois SD, Vander Velde DG, Siahaan TJ, Wang B, Borchardt RT.
    J Pept Res; 1999 Apr 01; 53(4):383-92. PubMed ID: 10406216
    [Abstract] [Full Text] [Related]

  • 18. In vitro stability and in vivo pharmacokinetic studies of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs.
    Yang JZ, Chen W, Borchardt RT.
    J Pharmacol Exp Ther; 2002 Nov 01; 303(2):840-8. PubMed ID: 12388671
    [Abstract] [Full Text] [Related]

  • 19. A comparison of the effects of p-glycoprotein inhibitors on the blood-brain barrier permeation of cyclic prodrugs of an opioid peptide (DADLE).
    Ouyang H, Andersen TE, Chen W, Nofsinger R, Steffansen B, Borchardt RT.
    J Pharm Sci; 2009 Jun 01; 98(6):2227-36. PubMed ID: 18855917
    [Abstract] [Full Text] [Related]

  • 20. Enhancing Oral Bioavailability of Cyclic RGD Hexa-peptides by the Lipophilic Prodrug Charge Masking Approach: Redirection of Peptide Intestinal Permeability from a Paracellular to Transcellular Pathway.
    Schumacher-Klinger A, Fanous J, Merzbach S, Weinmüller M, Reichart F, Räder AFB, Gitlin-Domagalska A, Gilon C, Kessler H, Hoffman A.
    Mol Pharm; 2018 Aug 06; 15(8):3468-3477. PubMed ID: 29976060
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.